Amarin Corp. PLC ADR | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
26,274.60
53,982.10
81,602.40
129,185.90
183,045.80
228,826.50
Cost of Goods Sold (COGS) incl. D&A
12,766.90
21,242.50
28,633.10
34,903.40
46,149.60
55,095.70
Gross Income
13,507.70
32,739.70
52,969.30
94,282.60
136,896.20
173,730.80
SG&A Expense
195,085.50
128,305.40
151,006.80
159,455.50
182,939.70
281,772.80
EBIT
181,577.80
95,565.80
-
65,172.90
46,043.40
108,042
Unusual Expense
47,571.60
51,297.10
207.60
8,113.60
-
-
Non Operating Income/Expense
1,185.60
3,711.90
227.60
478.70
74.80
325.50
Interest Expense
34,079.90
18,499.70
20,142.10
18,548.10
9,870.70
8,857
Pretax Income
168,929.50
58,960.90
118,067.80
75,853.70
55,405.80
116,152.30
Income Tax
3,184.70
2,825.50
3,080.20
9,900.20
13,186.90
95.80
Consolidated Net Income
165,744.80
56,135.40
148,779.00
85,753.90
68,592.60
116,248.10
Net Income
165,744.80
56,135.40
148,779.00
85,753.90
68,592.60
116,248.10
Net Income After Extraordinaries
165,744.80
56,135.40
148,779.00
85,753.90
68,592.60
116,248.10
Net Income Available to Common
165,744.80
56,135.40
148,779.00
85,753.90
68,592.60
116,248.10
EPS (Basic)
1.03
0.32
0.83
0.41
0.25
0.39
Basic Shares Outstanding
161,022.00
173,719.00
180,654.00
211,874.00
270,652.00
297,237
EPS (Diluted)
1.28
0.36
0.82
0.40
0.25
0.39
Diluted Shares Outstanding
167,070.00
173,824.00
180,654.00
211,874.00
270,652.00
297,237
EBITDA
180,688.30
94,725.20
97,227.00
64,395.30
45,327.90
107,374.20
Non-Operating Interest Income
342.00
95.60
131.80
232.40
433.60
1,072.20
Other After Tax Income (Expense)
-
-
33,791.40
-
-
-

About Amarin Corp.

View Profile
Address
2 Pembroke House
Dublin Dublin 2
Ireland
Employees -
Website http://amarincorp.com
Updated 07/08/2019
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It's product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.